From UBS...
The Plasma Protein Therapeutics Association produces monthly data on plasma distribution volumes in the USA. According to its April figures, CSL’s immunoglobulin (IG) business grew 13.9% (12-month rolling basis). This was slightly up from March’s 13.8%.UBS forecasts a decline in plasma collection of -20% for the April-September period owing to covid-19 induced restrictions. This in turn reduces forecasts for IG/albumin volumes by -20% for the first half of FY21.The broker highlights every -5% reduction in plasma collections over a 6-month period translates to a circa -2% earnings downgrade for the year.The company will be releasing its FY20 results on August 19.UBS retains its Buy rating with a target price of $331.
- Forums
- ASX - By Stock
- CSL
- Short CSL ? HCQ is the Cure
Short CSL ? HCQ is the Cure, page-12
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$294.13 |
Change
-0.870(0.29%) |
Mkt cap ! $142.4B |
Open | High | Low | Value | Volume |
$295.01 | $296.50 | $293.51 | $164.4M | 558.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 136 | $294.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$294.13 | 250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 136 | 294.100 |
1 | 2500 | 294.000 |
1 | 1274 | 293.860 |
1 | 34 | 293.850 |
1 | 1274 | 293.700 |
Price($) | Vol. | No. |
---|---|---|
294.130 | 250 | 1 |
294.170 | 949 | 1 |
294.190 | 750 | 1 |
294.240 | 594 | 1 |
294.270 | 46 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online